Loading
EB-CAR30-NK is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for thymoma and thymic carcinoma, aimed at CD30.
EB-CAR30-NK is a CAR-NK cell therapy developed by Beijing Biotech. Its target is CD30. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in thymoma and thymic carcinoma. The largest, NCT07598955, plans to enrol 36 participants with primary completion expected 2027-06-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
CAR-NK cell therapy directed at CD30, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to CD30.
1.EB-CAR30-NK slips into a pocket on CD30.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EB-CAR30-NK" OR ABSTRACT:"EB-CAR30-NK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EB-CAR30-NK, not a curated reading list.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma.
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma.